Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

Novo Nordisk announced that it has entered into a research collaboration and option agreement with Kallyope, Inc. a privately-held New York biotechnology platform developer, with the aim of developing novel therapies for diabetes and obesity.